Switching from rituximab to eculizumab in patients with AQP4+NMOSD in the United States: Impact on hospitalisations and comorbidities

被引：0
|
作者：
Lee, Justin [1 ]
Kielhorn, Adrian [1 ]
Fam, Sami [1 ]
Riser, Emily [2 ]
Flanagan, Eoin [3 ]
机构：
[1] Alexion, AstraZeneca Rare Dis, Boston, MA USA
[2] Alabama Neurol Associates, Birmingham, AL USA
[3] Mayo Clin, Dept Neurol, Rochester, MN USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P358/1445
引用
收藏
页码：391 / 392
页数：2
相关论文
共 50 条
  • [1] Impact Of Eculizumab On Quality Of Life In AQP4+NMOSD: Findings From The PREVENT Study
    Berthele, A.
    Pittock, S.
    Fujihara, K.
    Kim, H.
    Levy, M.
    Palace, J.
    Nakashima, I.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K.
    Pace, A.
    Fujita, K. P.
    Yountz, M.
    Armstrong, R.
    Wingerchuk, D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 105 - 106
  • [2] Impact Of Eculizumab On Hospitalization Rates And Relapse Treatment In Patients With AQP4+NMOSD: The Phase 3 PREVENT Study
    Kim, H.
    Pittock, S.
    Berthele, A.
    Fujihara, K.
    Levy, M.
    Palace, J.
    Nakashima, I.
    Terzi, M.
    Totolyan, N.
    Viswanathan, S.
    Wang, K.
    Pace, A.
    Fujita, K. P.
    Yountz, M.
    Armstrong, R.
    Wingerchuk, D.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 105 - 105
  • [3] Chronic Cognitive Impairment in AQP4+NMOSD With Improvement in Cognition on Eculizumab: A Report of Two Cases
    Saab, Georges
    Munoz, David G.
    Rotstein, Dalia L.
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [4] Safety Findings in Patients With AQP4+NMOSD Who Received Eculizumab or Ravulizumab in the PREVENT and CHAMPION-NMOSD Studies and Had Received Rituximab Within 1 Year Prior to Enrolment
    Levy, Michael
    Parks, Becky
    Allen, Kerstin
    Mujeebuddin, Arshad
    Taney, Melissa
    Mashhoon, Yasmin
    de Seze, Jerome
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1067 - 1067
  • [5] The difference of intercellular cytokine profiles among MOG+CNS disorders, AQP4+NMOSD, and MS patients
    Liu, J.
    Mori, M.
    Sugimoto, K.
    Uzawa, A.
    Uchida, T.
    Masuda, H.
    Ohtani, R.
    Isose, S.
    Arai, K.
    Kuwabara, S.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 836 - 836
  • [6] Long-term eculizumab in AQP4+NMOSD: relapse-risk reduction and safety in PREVENT and its completed open-label extension
    Berthele, A.
    Wingerchuk, D.
    Fujihara, K.
    Palace, J.
    Levy, M.
    Kim, H.
    Nakashima, I.
    Oreja-Guevara, C.
    Wang, K.
    Shang, S.
    Yountz, M.
    Pittock, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 63 - 64
  • [7] Long-Term Eculizumab in AQP4+NMOSD: Relapse-Risk Reduction and Safety in PREVENT and its Completed Open-Label Extension
    Berthele, Achim
    Wingerchuk, Dean
    Fujihara, Kazuo
    Palace, Jacqueline
    Levy, Michael
    Kim, Ho Jin
    Nakashima, Ichiro
    Oreja-Guevara, Celia
    Wang, Kai-Chen
    Shang, Shulian
    Yountz, Marcus
    Pittock, Sean
    NEUROLOGY, 2022, 99 (23) : S3 - S4
  • [8] Safety and Effectiveness of Eculizumab in Japanese Patients with Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (AQP4+NMOSD): Interim Analysis of a Post-Marketing Surveillance Study
    Nakahara, Jin
    Nakashima, Ichiro
    Yokote, Hiroaki
    Manabe, Yasuhiro
    Okamura, Kazumi
    Hasegawa, Kou
    Fujihara, Kazuo
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (07) : NP25 - NP25
  • [9] Severe Myelitis After a Long Interval of 20 Years From anEarlier Optic Neuritis Episode in Undiagnosed AQP4+NMOSD
    Tan, HuiJieh
    VernEw, Ju
    Wong, Daniel Yi Jie
    Eow, Gaik Bee
    Hor, JyhYung
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP94 - NP94
  • [10] Long-term burden of attacks in patients with AQP4+NMOSD: a simulation study based on results of a network meta-analysis
    Kielhorn, A.
    Johnston, K.
    Powell, L.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 143 - 144
12345